Characterization of novel Contilisant+Tubastatin A Multi-Target Small Molecules with against glioblastoma

ABSTRACT: Glioblastoma is the most common and aggressive primary brain tumor in adults, with patient prognosis remaining poor. Treatment resistance and tumor recurrence are frequent, primarily due to the high intra- and inter-tumoral heterogeneity and the presence of glioma stem cells. Thus, there is an urgent need for novel and more effective therapeutic strategies. Multitarget small molecules (MSMs) are emerging as a novel therapeutic strategy for the treatment of complex diseases such as cancer. In the present work, we have generated a novel family of indole-based MSMs with pharmacophoric moieties combining the parent compounds Contilisant and HDAC inhibitor Tubastatin A. Thus, the MSMs were designed to inhibit monoamine oxidases (MAOs), cholinesterases (ChEs) and histone deacetylases (HDACs), while acting as histamine H3 receptor (H3R) antagonists and sigma 1 receptor (S1R) agonists. We generated 4 different molecules and we focused on evaluating the activity of the 2 most efficient MSM compounds against glioblastoma, both in vitro and in vivo. In silico analyses indicated that these compounds are theoretically capable of crossing the blood–brain barrier, while exhibiting low toxicity in healthy cells. OMICs-based analyses further revealed that the compounds induce dysregulation of the cell cycle and alter neurotransmission-related activity in glioma stem cells. In conclusion, our findings demonstrate the potential antitumor activity of these compounds in preclinical models of glioblastoma.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

DISEASE(S): Brain Glioblastoma Multiforme

SUBMITTER: Mikel Azkargorta  

LAB HEAD: Felix Elortza

PROVIDER: PXD069713 | Pride | 2026-01-05

REPOSITORIES: Pride